Business description
Sandoz is a pharmaceutical company that develops, supplies, and markets a wide range of products, including pharmaceuticals, prescription drugs, biosimilars, generic antibiotics, dermatology, and transplantation products. It also offers generic cardiovascular therapeutics, central nervous system therapeutics, pain relievers, eye care products, oncology, respiratory and hormone therapeutics, and off-patent medicines. Founded in 1886, the company is headquartered in Basel, Switzerland.
Management board & Supervisory board
| CEO |
| Richard Saynor |
| Management board |
| Remco Steenbergen, Claire D’Abreu-Hayling, Francisco Ballester, Christophe Delenta, Glenn A. Gerecke, PhD, Rebecca Guntern, Keren Haruvi, Tripti Jha, Ingrid Sollerer |
| Supervisory board |
| Gilbert Ghostine, Dr. Karen J. Huebscher, Remco Steenbergen, Mathai Mammen, Graeme Pitkethly, Michael Rechsteiner, Urs Riedener, Dr. Shamiram R. Feinglass, Aarti Shah, PhD, Ioannis Skoufalos, Maria Varsellona |
Company data
| Name: |
Sandoz Group N |
| Address: |
Suurstoffi 14,6343 Rotkreuz |
| Phone: |
+41 61 324 11 11 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.sandoz.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
95.59% |
| IPO date: |
04/10/2023 |
